Impact of Cytomegalovirus Infection in Lung Transplant Patients Under Universal Prophylaxis: Single-Center Experience in Brazil

Abstract

Introduction Cytomegalovirus (CMV) infection, a common complication in lung transplant (LT) patients, is associated with worse outcomes. Therefore, prophylaxis and surveillance with preemptive treatment is recommended. Objectives Describe the epidemiology and impact on mortality of CMV infection in LT patients receiving CMV prophylaxis. Methods Single-center retrospective cohort of LT recipients from August 2003 to March 2008. We excluded patients with survival or follow-up shorter than 30 days. We reviewed medical charts and all CMV pp65 antigen results. Results Forty-seven patients met the inclusion criteria and 19 (40%) developed a CMV event: eight CMV infections, seven CMV syndromes, and 15 CMV diseases. The mean number of CMV events for each patient was 1.68 ± 0.88. Twelve patients developed CMV events during prophylaxis (5/12 had CMV serology D+/R−). Forty-six of the 47 patients had at least one episode of acute rejection (mean 2.23 ± 1.1). Median follow-up was 22 months (range = 3–50). There were seven deaths. Upon univariate analysis, CMV events were related to greater mortality ( P = .04), especially if the patient experienced more than two events ( P = .013) and if the first event occurred during the first 3 months after LT ( P = .003). Nevertheless, a marginally significant relationship between CMV event during the first 3 months after LT and mortality was observed in the multivariate analysis (hazards ratio: 7.46; 95% confidence interval: 0.98–56.63; P = .052). Patients with CMV events more than 3 months post-LT showed the same survival as those who remained CMV-free. Conclusion Prophylaxis and preemptive treatment are safe and effective; however, the patients who develop CMV events during prophylaxis experience a worse prognosis.